Atossa Therapeutics (ATOS) vs Polyrizon (PLRZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polyrizon (PLRZ) has outperformed Atossa Therapeutics (ATOS) over the past year, gaining 23.2% versus a loss of 85.5%. Polyrizon is the larger company by market cap ($22.3 million vs $21.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | PLRZ |
|---|---|---|
| Share price | $2.19 | $9.19 |
| Market cap | $21.81M | $22.32M |
| 1-day change | -9.70% | +3.61% |
| YTD return | -72.66% | +4.48% |
| 1-year return | -85.47% | +23.19% |
| 5-year return | -94.36% | — |
| EPS (TTM) | $-4.45 | $-4.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.00 | $18.20 |
| 52-week low | $1.70 | $2.88 |
| Distance from 52-week high | -87.86% | -49.51% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +769.49% | — |
| Average volume | 63.48K | 60.55K |
| Shares outstanding | 9.98M | 2.43M |
| Employees | 16 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRZ has outperformed ATOS by 108.7 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Polyrizon
PLRZ stock →Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Health Care · Medical/Dental Instruments · 2 employees
ATOS vs PLRZ FAQ
Which is bigger, Atossa Therapeutics or Polyrizon?
Polyrizon (PLRZ) is larger, with a market capitalization of $22.32M compared with $21.81M for Atossa Therapeutics (ATOS).
Which stock has performed better over the past year, ATOS or PLRZ?
PLRZ returned +23.19% over the past 12 months, compared with -85.47% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Polyrizon in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Atossa Therapeutics and Medical/Dental Instruments for Polyrizon.